EMEA-003152-PIP01-21

EMA/PE/0000246904

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Verquvo, vericiguat, Date of authorisation: 16/07/2021, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tecovirimat SIGA, tecovirimat monohydrate, Date of authorisation: 06/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Sitagliptin SUN, sitagliptin fumarate, Date of authorisation: 09/12/2021, Revision: 3, Status: Authorised

European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties meeting with all eligible organisations - 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 November 2025 to 19 November 2025

Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 11, Status: Authorised

Libtayo